Innoviva, Inc. (INVA)
| Market Cap | 1.75B |
| Revenue (ttm) | 411.33M |
| Net Income (ttm) | 271.17M |
| Shares Out | 74.05M |
| EPS (ttm) | 3.30 |
| PE Ratio | 7.18 |
| Forward PE | 11.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 530,404 |
| Open | 23.50 |
| Previous Close | 23.36 |
| Day's Range | 23.46 - 23.89 |
| 52-Week Range | 16.52 - 25.15 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 32.80 (+38.46%) |
| Earnings Date | May 7, 2026 |
About INVA
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use ... [Read more]
Financial Performance
In 2025, Innoviva's revenue was $411.33 million, an increase of 14.67% compared to the previous year's $358.71 million. Earnings were $271.17 million, an increase of 1059.22%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for INVA stock is "Buy." The 12-month stock price target is $32.8, which is an increase of 38.46% from the latest price.
News
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of...
Innoviva Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Innoviva highlighted robust growth across its royalty, specialty therapeutics, and strategic healthcare asset segments, with strong cash flow and multiple catalysts expected in 2026. Key products like GIAPREZA, XACDURO, ZEVTERA, and NUZOLVENCE are driving sales, while Armata and other assets offer significant upside.
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENC...
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
The U.S. Food and Drug Administration has approved Innoviva's oral antibiotic for common sexually transmitted infection, offering patients a pill instead of the injection that is currently the only re...
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial ...
Innoviva Transcript: Piper Sandler 37th Annual Healthcare Conference
A diversified healthcare business is leveraging strong royalty streams, a rapidly growing specialty therapeutics portfolio, and strategic investments to drive growth and value. Key hospital products are expanding through differentiated assets and robust patent protection, with $500 million in cash supporting further acquisitions and shareholder returns.
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ -- Antheia , the pharmaceutical ingr...
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America's ...
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that it will deliver data from six presentations at IDWeek 2025, includ...
Innoviva Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A diversified business structure supports strong financial performance, with royalty and therapeutics platforms both delivering robust growth. Multiple innovative products, including recent launches and a late-stage pipeline, position the company for continued expansion and resilience.
Innoviva Transcript: Cantor Global Healthcare Conference 2025
The company operates three segments: royalties, specialty therapeutics, and strategic healthcare assets, all showing strong momentum. Specialty therapeutics is growing rapidly with new product launches, while the royalty business remains stable and strategic investments are focused on high-potential assets.
Innoviva Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The event detailed a diversified strategy across royalties, specialty therapeutics, and strategic healthcare assets, emphasizing resilience, growth, and opportunistic investment. Recent performance showed strong growth in therapeutics and stable royalties, with upcoming product launches and regulatory milestones expected to drive further expansion.
Innoviva Transcript: Citi's Biopharma Back to School Conference
Three business pillars drive growth: stable GSK royalties, a rapidly expanding IST platform, and a diversified healthcare asset portfolio. Strong IP protection and international growth support royalty durability, while IST and strategic investments target high unmet needs and value creation.
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
WALTHAM, Mass.--(BUSINESS WIRE)--Prix Galien Award 2025.
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partn...
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
WALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Deve...
Innoviva Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
The business has evolved into a diversified model with stable royalty revenues, a rapidly growing infectious disease and critical care segment, and a strategic healthcare asset portfolio. Key catalysts include the U.S. launch of Zevtera and potential new product approvals, with strong growth and downside protection embedded in the model.
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobipro...
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and...